ArticleLancet regional health. Americas2025
The cost-effectiveness of tafenoquine following screening with STANDARD™ G6PD screening for the treatment of vivax malaria in the Brazilian Public Health System.
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vivax malaria requires radical cure to clear both the blood-stage and liver-stage parasites. Brazil, like most endemic countries, has been prescribing a 7-day primaquine regimen for radical cure without testing for glucose-6-phosphate-dehydrogenase (G6PD) deficiency to exclude those at risk of primaquine-induced haemolysis. Tafenoquine, a new single-dose drug for radical cure requires G6PD screening before prescription to ensure safety. This study aims to assess the cost-effectiveness of prescribing tafenoquine after semi-quantitative G6PD screening from the Brazilian Public Health System perspective. Methods: A decision tree model was developed for adults presenting with vivax malaria over 12-months. The Findings: The Interpretation: The prescription of tafenoquine to those who test G6PD normal with a semi-quantitative test is a cost-effective strategy for the radical cure of vivax malaria in Brazil. While the cost-effectiveness in other settings may vary due to differences in costs and the epidemiology of vivax malaria and G6PD deficiency, the robustness of these findings should be reassuring, particularly where healthcare facilities expect to see a large number of patients annually. Funding: Medicines for Malaria Ventures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.